Plain-English translation of NCT07224906 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is an observational study — meaning researchers will watch and collect data, not test a medication. The study is gathering information about how the HemoCept device performs during a diagnostic heart procedure called right heart catheterization. This procedure measures pressures and function in the right side of your heart, and the device will help monitor this process.
Right heart catheterization is an important diagnostic tool for patients with heart and lung conditions, but doctors want to better understand how new monitoring devices can improve safety and accuracy during this procedure.
You likely qualify if…
You likely don't qualify if…
You would undergo your scheduled heart catheterization procedure as planned, and the HemoCept device would be used to monitor your heart during the test. Researchers would collect data from the device during your procedure. The study is observational, so you would not receive any new medication or experimental treatment — the device is simply being monitored alongside your standard care.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Enrollment target
~50 participants
Started
December 2025
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Katharine Adkins
HemoCept Inc.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.